Chronic Kidney Disease
Part of NephTimes
Advertisement
Researchers examined the long-term safety of oral hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia of CKD.
What is the effect on CKD prevalence of adopting the race-free equation for eGFR in a US military population?
Researchers studied the feasibility of implementing a smartphone support tool for patients with both CKD and hypertension.
Archer Materials is working on detection and monitoring of CKD on its biochip graphene field effect transistor sensors.
The National Kidney Foundation is launching an online learning tool for adults with chronic kidney disease (CKD).
ProKidney halted one of two phase 3 trials of rilparencel, or REACT, a cell therapy for kidney disease.
Hilary Hatch discussed a survey finding that patient-provider conversations and patient activation play a key role in CKD.
A study examined the association of HbA1c with mortality in patients with chronic kidney disease and type 2 diabetes.
Little has been published about the risks of dehydration for children with chronic kidney disease (CKD).
Dr. Charles Vega spoke with Nephrology Times about the disproportionate chronic kidney disease burden among Latinos.
What is behind the higher incidence of kidney failure among Black versus White adults?
A National Kidney Foundation (NKF) working group has provided guidance on the use of genetic testing for kidney diseases.
Researchers have developed the most extensive single-cell atlas of the kidney, which may allow for better CKD prognosis.
The American Heart Association has launched a 4-year plan to improve awareness and treatment of CKM syndrome.
Could a lifestyle intervention intended for overweight or obese diabetes patients improve kidney function?
The FDA approved Velphoro (sucroferric oxyhydroxide) for hyperphosphatemia in patients with CKD as young as age 9.
Dialysis Patient Citizens has launched a first-in-the-nation kidney disease training curriculum for community health workers.
Researchers studied the efficacy of a community pharmacist-led nutritional intervention for outpatients with CKD.
The Kidney Foundation of Canada is seeking feedback through a survey to inform development of a national CKD framework.
Akebia Therapeutics has ended its license agreement with CSL Vifor for Vafseo and announced WAC pricing for the anemia drug.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.